Association of beta-endorphin with specific clinical symptoms of depression
1992; American Psychiatric Association; Volume: 149; Issue: 9 Linguagem: Inglês
10.1176/ajp.149.9.1162
ISSN1535-7228
AutoresDenis F. Darko, Risch Sc, J. Christian Gillin, S Golshan,
Tópico(s)Tryptophan and brain disorders
ResumoBack to table of contents Previous article Next article No AccessAssociation of beta-endorphin with specific clinical symptoms of depressionPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.149.9.1162AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractOBJECTIVE: Abnormalities in plasma concentrations of beta-endorphin- like immunoreactivity (beta-endorphin) have been reported in depressed patients. This study was done to test the hypothesis that specific clinical characteristics of depression are associated with plasma beta- endorphin concentration. METHOD: Plasma beta-endorphin was evaluated in 20 depressed patients diagnosed according to DSM-III-R and in 23 age- and sex-matched comparison subjects, and each was evaluated with the structured Schedule for Affective Disorders and Schizophrenia (SADS). Twelve SADS items involving dysphoric mood and related symptoms were chosen for analysis. RESULTS: Within the group of all 43 subjects and within the depressed group, beta-endorphin level correlated significantly with psychic anxiety and with phobia. In the depressed group only, beta-endorphin also correlated significantly with obsessions/compulsions. Concentration of beta-endorphin was not significantly correlated with score on the Hamilton Rating Scale for Depression or Beck Depression Inventory or with scores on other SADS symptom items, including somatic anxiety, insomnia, subjective anger, overt anger, agitation, psychomotor retardation, panic attacks, appetite loss, or total weight loss. In the group of 23 comparison subjects, beta-endorphin did not correlate with Beck or Hamilton depression score or with any of the SADS clinical variables. CONCLUSIONS: High levels of plasma beta-endorphin may be associated with more severe anxiety, phobia, and obsessions/compulsions in depressed patients. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byEvidence of alterations of Beta-endorphin levels and Mu-opioid receptor gene expression in bipolar disorderPsychiatry Research, Vol. 316Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target EngagementBiological Psychiatry Global Open Science, Vol. 2, No. 2Multiple Sclerosis and the Endogenous Opioid System17 September 2021 | Frontiers in Neuroscience, Vol. 15Circulating levels of β-endorphin and cortisol in breast cancerComprehensive Psychoneuroendocrinology, Vol. 5Supplementation with Matured Hop Bitter Acids Improves Cognitive Performance and Mood State in Healthy Older Adults with Subjective Cognitive DeclineJournal of Alzheimer's Disease, Vol. 76, No. 1Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality25 March 2020 | CNS Drugs, Vol. 34, No. 6Self-Injuring Behavior and Mental Illness in Opioid-Dependent Patients Treated with Implant Naltrexone, Methadone, and Buprenorphine in Western Australia20 December 2017 | International Journal of Mental Health and Addiction, Vol. 16, No. 1, Vol. 247Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins15 July 2016Brain Research, Vol. 1652Journal of Affective Disorders, Vol. 181Alcoholism: Clinical and Experimental Research, Vol. 39, No. 1Vestnik otorinolaringologii, Vol. 80, No. 1Antidepressant-like and anxiolytic-like effects following activation of the μ-δ opioid receptor heteromer in the nucleus accumbens24 September 2013 | Molecular Psychiatry, Vol. 19, No. 9Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in micePharmacology Biochemistry and Behavior, Vol. 124Stress and Neuroendocrine–Immune Interaction: A Therapeutic Role for β‐endorphin1 November 2013European Neuropsychopharmacology, Vol. 23, No. 12Acupuncture for Depression: A Review of Clinical Applications1 July 2012 | The Canadian Journal of Psychiatry, Vol. 57, No. 7Regulation of Cancer Progression by β-Endorphin Neuron14 February 2012 | Cancer Research, Vol. 72, No. 4Brain Research Bulletin, Vol. 88, No. 6European Journal of Pain, Vol. 16, No. 1Opioids and anxiety8 June 2010 | Journal of Psychopharmacology, Vol. 25, No. 11Novel Therapeutic Approaches for Treating Bipolar Disorder14 April 2011Depression and Anxiety, Vol. 28, No. 4Irish Journal of Medical Science, Vol. 180, No. 2European Journal of Pharmacology, Vol. 658, No. 2-3Alcoholism: Clinical and Experimental Research, Vol. 34, No. 6Opposite effects of opioid blockade on the blood pressure–pain relationship in depressed and non-depressed participantsPain, Vol. 142, No. 1Behavioural Brain Research, Vol. 200, No. 1Neuropeptides, Vol. 43, No. 5The International Journal of Neuropsychopharmacology, Vol. 12, No. 08Stress-evoked opioid release inhibits pain in major depressive disorderPain, Vol. 139, No. 2Immunology Letters, Vol. 118, No. 1Towards a possible aetiology for depressions?14 September 2007 | Behavioral and Brain Functions, Vol. 3, No. 1European Journal of Pharmacology, Vol. 576, No. 1-3Neuropsychopharmacology, Vol. 32, No. 4Pharmacological Reviews, Vol. 59, No. 1European Journal of Neuroscience, Vol. 23, No. 4, Vol. 15Neuroscience Letters, Vol. 381, No. 3Pharmacology Biochemistry and Behavior, Vol. 82, No. 3Biological Psychiatry, Vol. 51, No. 6Neuroscience, Vol. 110, No. 3Journal of Neurochemistry, Vol. 73, No. 6Sports Medicine, Vol. 32, No. 12BibliographyEuropean Journal of Pharmacology, Vol. 354, No. 1Life Sciences, Vol. 63, No. 12Personality and Individual Differences, Vol. 26, No. 1Medical Hypotheses, Vol. 51, No. 4Human Psychopharmacology: Clinical and Experimental, Vol. 12, No. 3Human Psychopharmacology: Clinical and Experimental, Vol. 12, No. 4Biological Psychiatry, Vol. 37, No. 6Pharmacology Biochemistry and Behavior, Vol. 52, No. 1Journal of Affective Disorders, Vol. 32, No. 4European Neuropsychopharmacology, Vol. 4, No. 3Nordic Journal of Psychiatry, Vol. 48, No. 6beta-Endorphin and specific clinical symptoms of depression1 April 2006 | American Journal of Psychiatry, Vol. 150, No. 11Dr. Darko and Colleagues ReplyDENIS F. DARKO, S. CRAIG RISCH, SHAHROKH GOLSHAN, and J. CHRISTIAN GILLIN1 April 2006 | American Journal of Psychiatry, Vol. 150, No. 11Correction1 April 2006 | American Journal of Psychiatry, Vol. 150, No. 11Peptides, Vol. 14, No. 6 Volume 149Issue 9 September 1992Pages 1162-1167 Metrics PDF download History Published online 1 April 2006 Published in print 1 September 1992
Referência(s)